Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, several of in-clinic treatment centers have announced they are closing their operations.
One of them is the famed Field Trip Health & Wellness Ltd. (OTC:FTHWF) which, "in an effort to reduce expenditures and preserve capital" will close its facilities in Chicago, Washington DC, Seattle, San Diego and Fredericton, Canada as of April 15, 2023.
Interestingly, not long ago a conference hosted by Cantor Fitzgerald analyst Pablo Zuanic, Chad ketamine therapy companies Field Trip, Irwin Naturals (OTC:IWINF) and Numinus Wellness (OTC:NUMIF) shared their views on the ketamine space, Irwin's CEO praised the value of Field Trip's offer.
Field Trip will provide clients with information on finding alternative care providers, how to access their medical records and other information required by applicable laws and regulations.
Moreover, the company's Independent Committee (IC) created last December to assess strategic options, along with financial and legal advisors, will "continue to review operations and investigate alternate courses of actions including, but not limited to, further cost reductions, restructuring, the potential sublease or closure of clinic locations and settlement of lease obligations."
See also: Field Trip H&W Closes Q3 2023 On Material Uncertainty, Need To Lower Costs & Adapt To New Regulations
Another major provider has also announced it will be shutting down its ketamine therapy clinic. Delic Holdings (OTC:DELCF)' acquired Ketamine Wellness Centers (KWC) have "suspended" their operations. While providing their patients the chance to obtain their records, no further public information was made available at the moment.
Although many ketamine therapy businesses are still thriving as patients treat their depression, anxiety, or other mental health conditions and PTSD, the almost concurrent announcements indicate that this might be more than a mere coincidence. Business, as we know, requires a wait-and-see (or in this case, inform) approach.
The second edition of the Benzinga Psychedelics Capital Conference is coming your way! The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.
Get your tickets now before prices go up!
Photo: Benzinga edit with photo by woraatep suppavas on Shutterstock and Doc James on Wikimedia Commons.
紧随着包括氯胺酮疗法在内的远程医疗新规定的宣布，几家诊所治疗中心已经宣布关闭他们的业务。
其中之一是著名的野外旅行健康与健康有限公司(场外交易代码：FTHWF)，该公司将于2023年4月15日起关闭其在芝加哥、华盛顿特区、西雅图、圣地亚哥和加拿大弗雷德里克顿的设施。
有趣的是，不久前由Cantor Fitzgerald分析师Pablo Zuanic、乍得氯胺酮治疗公司field Trip、Irwin Naturals(场外交易代码：IWINF)和Nnuus Wellness(场外交易代码：NUMIF)主办的一次会议分享了他们对氯胺酮领域的看法，Irwin的首席执行官称赞了field Trip的报价的价值。
实地考察旅行将向客户提供有关寻找替代护理提供者、如何获取他们的医疗记录以及适用法律和法规要求的其他信息的信息。
此外，该公司去年12月成立的独立委员会(IC)将与财务和法律顾问一起评估战略选择，将“继续审查运营并调查替代行动方案，包括但不限于进一步降低成本、重组、可能转租或关闭诊所地点以及清偿租赁义务。”
另请参阅：实地考察H&W因材料不确定性而结束2023年第三季度，需要降低成本并适应新法规
另一家主要供应商也宣布将关闭其氯胺酮治疗诊所。Delic Holdings(场外交易代码：DELCF)收购的氯胺酮健康中心(KWC)已经“暂停”运营。虽然他们的病人有机会获得他们的记录，但目前没有进一步的公开信息。
尽管许多氯胺酮治疗业务仍在蓬勃发展，因为患者正在治疗他们的抑郁、焦虑或其他精神健康状况和创伤后应激障碍，但几乎同时宣布的消息表明，这可能不仅仅是巧合。正如我们所知，商业需要一种观望(或在这种情况下，通知)的方式。
T他本辛加迷幻药资本会议第二版正在向你走来！活动将于2023年4月13日在佛罗里达州的枫丹白露迈阿密海滩酒店举行。这里是达成交易、筹集资金、启动并购、会见投资者和关键合作伙伴的地方。
现在就去买票吧在物价上涨之前！
图片：Benzinga在Shutterstock上由woraatep suppaas编辑，Doc James在维基媒体上编辑。
